Market Overview

Acceleron's Pulmonary Arterial Hypertension Asset Receives Orphan Drug Designation

Share:
Acceleron's Pulmonary Arterial Hypertension Asset Receives Orphan Drug Designation

Cambridge, Massachusetts-based Acceleron Pharma Inc (NASDAQ: XLRN) said Monday that the FDA has accorded Orphan Drug Designation to its sotatercept.

The drug is an investigational asset to treat pulmonary arterial hypertension, or PAH. Sotatercept is a selective ligand trap for members of the TGF-beta superfamily to rebalance BMPR2 signaling, which is a key driver of PAH.

An ODD is granted by the FDA to facilitate development of effective and safe therapies for rare diseases that affect fewer than 200,000 people in the U.S.

The benefits of an ODD include grants for meeting clinical trial costs, tax advantages, FDA user-fee benefits and seven years of market exclusivity in the U.S. following FDA approval.

Sotatercept, which hasn't been approved in any country, is being evaluated in two Phase 2 trials — dubbed PULSAR and SPECTRA — in patients with PAH.

Acceleron expects to report top-line results from the PULSAR trial in the first quarter of 2020. 

Enrollment is underway for the SPECTRA study, which is an exploratory trial.

Acceleron shares were trading higher by 1.27% at $45.10 at the time of publication Monday. 

Related Links:

The Week Ahead In Biotech: Conference Presentations, IPO News Flow Take The Spotlight

Biotech Stock On The Radar: Ardelyx Gears Up For FDA Decision Day

Posted-In: Biotech News FDA Trading Ideas Best of Benzinga

 

Related Articles (XLRN)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Roadrunner Announces New CFO

Medicine Man Technologies To Operate 27 Dispensaries in Colorado